Astellas Jump-Starts Ophthalmology Ambitions With Ocata Buy
This article was originally published in PharmAsia News
Executive Summary
Astellas's planned $379m purchase of US regenerative medicine venture Ocata will give the Japanese firm a new presence in ophthalmology and strengthen its cell therapy capabilities.